Media Room

30.11.2021

First patients have been enrolled in a Ph3 lung cancer study by a US biotech

OCT Clinical has successfully initiated patient recruitment for the clinical trial in a Ph3 lung cancer study in Russia. This is a randomized open-label trial, the aim of which is to determine the efficacy and safety of a test drug in combination with chemotherapy and platinum as first-line therapy in patients with metastatic non-squamous cell non-small cell lung cancer. The Sponsor of a study is a U.S.-based immuno-oncology biotech company.

The recruitment target for the entire global study is 560 patients in four countries: Russia, Ukraine, Georgia, and Belarus. The site initiation in Ukraine, Georgia, and Belarus is planned for January 2022. Participants will be treated until the disease progresses or intolerance to therapy develops. The duration of the project is almost 4 years, until the end of 2024. 

Within this project, the OCT Clinical team is responsible for a wide scope of clinical trial services: study feasibility analysis and site selection, clinical trial approval and regulatory support, logistics, medical monitoring, project management, site management and monitoring.

Thank you for your request!
Our team will respond to you within 24 hours.